Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3141 Results for "
mSWI/SNF complex
" in MedChemExpress (MCE) Product Catalog:
Products (3141)
3141 Results for "mSWI/SNF complex" in MCE Product Catalog:
Cat. No.: HY-P86815
Synonyms: ATP/GTP binding protein antibody; Cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; ATP/GTP binding protein antibody; Cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; Polyadenylation factor Clp1 antibody; Polynucleotide kinase Clp1 antibody; Polyribonucleotide 5' hydroxyl kinase Clp1 antibody; Polyribonucleotide 5''-hydroxyl-kinase Clp1 antibody; Pre mRNA cleavage complex II protein Clp1 antibody; Pre-mRNA cleavage complex II protein Clp1 antibody;
Cat. No.: HY-169385
CAS No.: 2925060-81-5
Target:
Research Areas:
ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
Cat. No.: HY-178736S
Synonyms: DLPE-d46; 1,2-Dilauroyl-sn-glycero-3-PE-d46
Cat. No.: HY-W015954R
CAS No.: 24347-58-8
Cat. No.: HY-L018
458 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.
MCE designs a unique collection of 458 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.
Cat. No.: HY-L936V0
11412 compounds
Molecular Glue Virtual Library is constructed using generative AI technology, integrating the structural features, activity data of known molecular glues, and interaction information of ternary complexes (target protein-E3-molecular glue). Endowed with structural novelty, drug-likeness, diversity and synthesizability, it is applicable to molecular glue-based AI drug screening and large-scale virtual screening.
MCE builds this library based on high-quality molecular building blocks by virtue of robust computing power, coupled with rigorous reaction rules and optimized compound generation strategies. To ensure library quality, molecules with high synthetic difficulty, poor drug-likeness, PAINS and other undesirable molecules are excluded first. Subsequently, scaffold-based compound analysis is performed to screen drug-like diverse molecules for synthesizability evaluation; those with excessively high synthetic difficulty are removed, ultimately forming a large-scale molecular glue virtual library with structural diversity, synthesizability and drug-likeness.
Compounds in the library can be synthesized in only 1-2 chemical reaction steps. With MCE’s experienced chemical synthesis team, custom synthesis of different scales from milligram to kilogram can be easily achieved to meet diverse customer needs.
Cat. No.: HY-P83718
Synonyms: FLJ25321 antibody;
HC5 antibody;
KIAA1838 antibody;
Macropain subunit C5 antibody;
Multicatalytic endopeptidase complex subunit C5 antibody;
Proteasome (prosome macropain) subunit beta type 1 antibody;
Proteasome beta 1 subunit antibody;
Proteasome component C5 antibody;
Proteasome gamma chain antibody;
Proteasome subunit beta type 1 antibody;
Proteasome subunit beta type-1 antibody;
Proteasome subunit HC5 antibody;
PSB1_HUMAN antibody;
PSC5 antibody;
PSMB 1 antibody;
PSMB1 antibody
Cat. No.: HY-P85514
Synonyms: Basic transcription factor 2 62 kDa subunit; Basic transcription factor 62 kDa subunit; BTF 2; BTF2; BTF2 p62; General transcription factor IIH polypeptide 1; General transcription factor IIH subunit 1; General transcription factor IIH, polypeptide 1, 62kDa; gtf2h1; TF2H1; TF2H1_HUMAN; TFB1; TFIIH; TFIIH basal transcription factor complex p62 subunit.
Cat. No.: HY-P811903
Synonyms: RMND5A; Required For Meiotic Nuclear Division 5 Homolog A; P44CTLH; GID2A; RMD5; GID2; E3 Ubiquitin-Protein Transferase RMND5A; 44-KD Protein Coding For CTLH Motif; GID complex Subunit 2 Homolog A; Protein RMD5 Homolog A; FLJ13910; Required For Meiotic Nuclear Division 5 Homolog A (S. Cerevisiae); C-Terminal To LisH Motif, 44 KDa; EC 2.3.2.27; CTLH
Cat. No.: HY-131384
CAS No.: 34262-64-1
Synonyms: 8,11,14-Icosatriynoic acid
Research Areas:
U7D-1 is a USP7 PROTAC degrader that induces selective proteasomal degradation of USP7. U7D-1 destabilizes and downregulates the expression of variant PRC1 complex subunits PCGF1, RING1A and PCGF6, and also slightly reduces the protein level of KDM2B. U7D-1 decreases cell viability, arrests neuroblastoma cells at the G0/G1 cell cycle phase, and downregulates the expression of target genes of PAX3::FOXO1 in FP-RMS cells. U7D-1 increases the level of cleaved PARP in FP-RMS cells, induces cell apoptosis, and upregulates the expression of muscle differentiation markers MYH1 and MYF5. U7D-1 inhibits the growth and proliferation of p53 wild-type and mutant cancer cells, and regulates the apoptosis pathway and E2F pathway. U7D-1 is applicable to studies on neuroblastoma, fusion-positive rhabdomyosarcoma, p53-mutant cancers and cancer-related research .
Cat. No.: HY-170524
CAS No.: 3052313-73-9
Research Areas:
TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
Cat. No.: HY-170820
CAS No.: 3006788-11-7
Target:
Molecular Glues Eukaryotic Release Factor (eRF) Bcl-2 Family CDK EGFR HSP Androgen Receptor c-Myc
Research Areas:
XYD049 is a CRBN-based molecular glue degrader targeting GSPT1, with a DC50 of 19 nM. XYD049 mediates the formation of a ternary complex between CRBN and GSPT1, thereby triggering CRBN- and proteasome-dependent degradation of GSPT1. By degrading GSPT1, XYD049 downregulates castration-resistant prostate cancer (CRPC)-related oncogenes, including BCL2, CDK2, E2F3, EGFR, HSP90B1, TMPRSS2, AR, AR-V7, PSA and c-Myc. XYD049 inhibits cancer cell growth and suppresses tumor growth in mice. XYD049 can be used for research on castration-resistant prostate cancer. XYD049 consists of a linker (black part) NH2-C5-NH-Boc (HY-W004710), a CRBN-based E3 ligase ligand (blue part) Thalidomide 4-fluoride (HY-41547), and a target protein ligand (red part) GSPT1 ligand-1 (HY-170821), among which the E3 ligase ligand plus linker forms the conjugate E3 Ligase Ligand-linker Conjugate 158 (HY-170822) .
Cat. No.: HY-174379
NTLiverTac PDE6D degrader-1 is a PDE6D NTLiverTac degrader with a DC50 of 4.09 μM. NTLiverTac PDE6D degrader-1 is formed by conjugating a PDE6D PROTAC degrader with the NTCP ligand Cholic acid (HY-N0324). NTLiverTac PDE6D degrader-1 triggers the ubiquitin-proteasome system-mediated degradation process by forming a complex with PDE6D and MDM2, inducing proteasome-dependent and NTCP-dependent degradation. NTLiverTac PDE6D degrader-1 inhibits PDE6D-dependent KRAS trafficking and suppresses KRAS-related oncogenic signaling cascades. NTLiverTac PDE6D degrader-1 inhibits the activation of the PI3K/AKT/mTOR signaling pathway and induces cellular Apoptosis. NTLiverTac PDE6D degrader-1 enters cancer cells via NTCP-mediated endocytosis. NTLiverTac PDE6D degrader-1 can be used in the research of hepatoblastoma (MDM2 ligand: (4R,5S)-Nutlin carboxylic acid (HY-128836); NTCP ligand: Cholic acid (HY-N0324); PDE6D ligand: Sorafenib (HY-10201)) .
Cat. No.: HY-182959
Research Areas:
Hsp70TAC PD-1 Degrader-2 is a PD-L1 Hsp70TAC (Hsp70-targeting Chimeras) degrader with Kd values of 0.36 μM. Hsp70TAC PD-1 Degrader-2 forms a ternary complex with Hsp70 and PD-L1 to drive PD-L1 degradation. Hsp70TAC PD-1 Degrader-2 induces degradation of mature membrane-bound PD-L1 in an Hsp70-dependent manner and via caveolin-mediated endocytosis and lysosomal trafficking. Hsp70TAC PD-1 Degrader-2 accumulates preferentially in tumor cells with elevated Hsp70 expression for tumor-selective PD-L1 degradation. Hsp70TAC PD-1 Degrader-2 can be used for the research of cancer, such as breast invasive carcinoma, glioblastoma multiforme, diffuse large b-cell lymphoma . (Pink: PD-1/PD-L1 ligand (HY-19745A); Blue: Hsp70 ligand (HY-182979); Black: linker (HY-182982)).
Cat. No.: HY-187731
CAS No.: 685141-23-5
BXL0124 is an orally effective CD44 inhibitor and Notch signaling pathway inhibitor. BXL0124 has a vitamin D receptor-dependent mechanism and can downregulate the expression of CD44, Notch1/2/3, HES1, OCT4, LAMA5, JAG1, JAG2, NF-κB and DLL1. BXL0124 inhibits c-Myc expression and the levels of phosphorylated ERK, AKT, ErbB2, reduces the level of activated Notch1 receptor and its nuclear localization, decreases the mRNA and protein levels of Jagged-1 and Jagged-2, and inhibits the STAT3 signaling pathway by reducing the formation of the CD44-STAT3-JAK2 complex, while also inhibiting the transcriptional activity of the CD44 promoter in a p53-dependent manner. BXL0124 can induce myoepithelial differentiation and inhibit the self-renewal of cancer stem cell-like cells, cancer cell proliferation, invasion, and growth. BXL0124 can be used in research related to triple-negative breast cancer, basal-like breast cancer, ErbB2-overexpressing mammary tumorigenesis, and breast cancer .
Cat. No.: HY-W657887
CAS No.: 154866-92-9
Target:
Histone Methyltransferase GSK-3 Tau Protein Amyloid-β Glucocorticoid Receptor Androgen Receptor Adrenergic Receptor
Research Areas:
GSK-3β/G9a-IN-1 (Compound T2) is an orally active, selective, blood-brain-barrier permeable, competitive G9a (substrate-competitive, IC50: 1.1 μM) and GSK-3β (ATP competitive, IC50: 0.8 μM) inhibitor. GSK-3β/G9a-IN-1 is a potent H3K9me2 inhibitor that reshapes chromatin landscape. GSK-3β/G9a-IN-1 lowers tau phosphorylation, reduces Aβ aggregation. GSK-3β/G9a-IN-1 displays inhibition toward glucocorticoid receptor, androgen receptor, and alpha-2A adrenergic receptor. GSK-3β/G9a-IN-1 also upregulates SAGA complex members such as Eny2 and Sgf29. GSK-3β/G9a-IN-1 markedly improves memory, restores social behaviors, and increases synaptic complexity in late-onset Alzheimer’s disease .
Cat. No.: HY-P85527
Synonyms: BRCA1/BRCA2 containing complex, subunit 5; BRCC 5; BRCC5; DNA repair protein RAD51 homolog 1; DNA repair protein rhp51; HRAD51; HsRad51; HsT16930; MRMV2; Rad 51; RAD51; RAD51 homolog; RecA homolog, E. coli; S. cerevisiae; RAD51 homolog A; RAD51 homolog; RAD51 recombinase; RAD51, S. cerevisiae, homolog of; RAD51_HUMAN; RAD51A; RECA; RecA like protein; RecA, E. coli, homolog of; Recombination protein A.
Cat. No.: HY-P86959
Synonyms: Activator recruited cofactor 240 kDa component antibody; Activator-recruited cofactor 240 kDa component antibody; ARC240 antibody; CAG repeat protein 45 antibody; CAGH45 antibody; HOPA antibody; KIAA0192 antibody; MED12 antibody; MED12_HUMAN antibody; Mediator complex subunit 12 antibody; Activator recruited cofactor 240 kDa component antibody; Activator-recruited cofactor 240 kDa component antibody; ARC240 antibody; CAG repeat protein 45 antibody; CAGH45 antibody; HOPA antibody; KIAA0192 antibody
Cat. No.: HY-P7S1354
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: S100A9; 60B8AG; Prev. CAGB; CGLB; Prev. CFAG; MIF; MRP-14; NIF; MRP14; Protein S100-A9; P14; Calgranulin B; Migration Inhibitory Factor-Related Protein 14; S100 Calcium-Binding Protein A9 (Calgranulin B); Leukocyte L1 complex Heavy Chain; S100 Calcium-Binding Protein A9; Calprotectin L1H Subunit; Calgranulin-B; S100-A9; L1AG; MAC387; S100 Calcium Binding Protein A9; LIAG
Species:
Rat
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
